Thyrocare Technologies Ltd operates within the Medical laboratories sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Thyrocare Technologies Ltd with three other
pharmaceutical manufacturers in Asia:
Malaysian Genomics Resource Centre Berhad
sales of 27.73 million Malaysian Ringgits [US$6.84 million]
Medical & Biological Laboratories Company Limited
(8.18 billion Japanese Yen [US$74.30 million]
of which 99%
was Reagent business), and
Scandent Imaging Ltd
(141.89 million Indian Rupees [US$2.00 million]
During the year ended March of 2019, sales at
Thyrocare Technologies Ltd were 4.03 billion Indian Rupees (US$56.69 million).
increase of 13.1%
versus 2018, when the company's sales were 3.56 billion Indian Rupees.
This was the fifth consecutive year of sales increases at Thyrocare Technologies Ltd
(and since 2014, sales have increased a total of 169%).
Sales of Imaging Services saw an increase
that was more than double the company's growth rate: sales were up
33.1% in 2019, from
245.22 million Indian Rupees to 326.40 million Indian Rupees.
Not all segments of Thyrocare Technologies Ltd experienced an increase in sales in 2019:
sales of Others fell 24.1% to 21.60 million Indian Rupees.
(However, this segment's sales were only a very small portion of the company's overall sales).